Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
CFR Kearney
Author(s): Laura Kearney , Paul Wright , Sadeer Fhadil , et al Added: 3 years ago
Postpartum cardiomyopathy (PPCM) is a diagnosis of exclusion, where patients present with heart failure secondary to left ventricular (LV) systolic dysfunction towards the end of pregnancy or in the months following delivery, with no other cause of heart failure identified.1 PPCM is relatively uncommon, affecting between one in 5,000 and one in 10,000 births;2 it is thought to be more prevalent… View more

Demographic

Heterogeneous Populations
Author(s): Tobias Koenig , Johann Bauersachs , Denise Hilfiker-Kleiner Added: 3 years ago
Cardiovascular diseases (CVD) are a major cause of complications in pregnancies worldwide, and can be largely attributed to increased cardiovascular risk factors, such as obesity and hypertensive disorders.1 Today, up to 4% of all pregnancies are complicated by CVD, with increasing frequency.2 Cardiomyopathies – whether inherited or acquired – represent the leading cause of maternal morbidity and… View more

Demographic
Hypertrophic Cardiomyopathy: Highlights From 2021 & Genetic Testing for HCM
Added: 2 years ago
In this hypertrophic cardiomyopathyseries, Dr Carolyn Ho, presents two videos discussing highlights of 2021 and genetic testing. View more

Heart Failure
T1 and T2 Mapping in Uremic Cardiomyopathy: An Update
Author(s): Luca Arcari , Giovanni Camastra , Federica Ciolina , et al Added: 2 years ago

Imaging & Diagnostics
ACC 22: Mavacamten in Patients with Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy
Author(s): Milind Y Desai Added: 2 years ago
In this short summary interview, Dr Milind Y Desai (Cleveland Clinic, US) shares the findings from the VALOR-HCM trial (MyoKardia) (NCT04349072). This randomised, multicentre study was designed to assess the effect of mavacamten treatment on reducing the number of septal reduction therapy (SRT) procedures performed in subjects with symptomatic obstructive hypertrophic cardiomyopathy. Discussion… View more

Vascular Disease and Surgery
HFA 23: REDWOOD-HCM-Cohort 4: Aficamten in symptomatic nHCM
Author(s): Ahmad Masri Added: 10 months ago
ESC-HFA 23 — We are joined by Dr Ahmad Masri (Oregon Health & Science University Medical Group, US) to discuss the findings from REDWOOD-HCM cohort 4 (NCT04219826). This study assessed the safety and tolerability of the selective inhibitor of cardiac myosin, aficamten (Cytokinetics) in patients with symptomatic nHCM. Cohort 4 included 41 patients. The data presented at HFA 23 shows that… View more

Heart Failure
AHA 22: Results of the CRISPR-Cas9 First-in-Human Trial
Author(s): Julian Gillmore Added: 1 year ago
AHA 2022 — Dr Julian Gillmore (University College London, London, UK) joins us to share the key findings from the CRISPR trial (NCT04601051). This phase 1 study was conducted to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of NTLA-2001 in participants with hereditary transthyretin amyloidosis with cardiomyopathy (ATTRv-CM) or wild type cardiomyopathy (ATTRwt… View more

Heart Failure
Author(s): Kenan Yalta , Mustafa Yılmaztepe , Cafer Zorkun Added: 3 years ago
In the past decades, takotsubo cardiomyopathy (TTC) has emerged as a specific form of acute and transient myocardial disease, predominantly affecting postmenopausal women in the clinical setting.1–4 In general, myocardial involvement in this setting appears to harbour a regional pattern particularly extending beyond the territory of a single coronary artery (and usually without concomitant… View more

Heart Failure
Role of Imaging in Cardiomyopathies
Author(s): Vincenzo Castiglione , Alberto Aimo , Giancarlo Todiere , et al Added: 11 months ago

Imaging & Diagnostics

Heart Failure